Abstract:<p></p><p>Phosphodiesterases(PDEs) are vital in signal transduction, specificallyby hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notablefor its prominence in the striatum and its regulatory function overneurotransmitters in medium-spiny neurons. Given the dopamine deficiencyin Parkinson’s disease (PD) that affects striatal pathways,PDE10A inhibitors could offer therapeutic benefits by modulating D1and D2 receptor signaling. This study was motivated by the successfulhistory of quinazoline/quinazoline scaffolds in the inhibition ofPDE10A. This study involved detailed in silico evaluationsthrough docking followed by pharmacological, pharmacophoric, and pharmacokineticanalyses, prioritizing central nervous system (CNS)-active drug criteria.Seven cyclic peptides, those featuring the quinazoline/quinazolinemoiety at both termini, exhibited notably enhanced docking scorescompared to those of the remaining alkaloids within the screened library.We identified 7 quinolines and 1 quinazoline including Lepadin G,Aspernigerin, CJ-13536, Aurachin A, 2-Undecyl-4(1H)-quinolone, Huajiaosimuline 3-Prenyl-4-prenyloxyquinolin-2-one,and Isaindigotone that followed the standard CNS active drug criteria.The dominant quinoline ring in our study and its related quinazolinewere central to our evaluations; therefore, the pharmacophoric featuresof these scaffolds were highlighted. The top alkaloids met all CNS-activedrug properties; while nonmutagenic and without PAINS alerts, manyindicated potential hepatotoxicity. Among the compounds, Huajiaosimulinewas particularly significant due to its alignment with lead-likenessand CNS-active criteria. Aspernigerin demonstrated its affinity fornumerous dopamine receptors, which signifies its potential to alterdopaminergic neurotransmission that is directly related to PD. Interestingly,the majority of these alkaloids had biological targets primarily associatedwith G protein-coupled receptors, critical in PD pathophysiology.They exhibit superior excretion parameters and toxicity end-pointscompared to the standard. Notably, selected alkaloids demonstratedstability in the binding pocket of PDE10A according to the moleculardynamic simulation results. Our findings emphasize the potential ofthese alkaloids as PDE10A inhibitors. Further experimental studiesmay be necessary to confirm their actual potency in inhibiting PDE10Abefore exploring their therapeutic potential in PD.</p>

Identification of Novel Quinolin-2(1 H )-ones as Phosphodiesterase 1 Inhibitors for the Treatment of Inflammatory Bowel Disease

Research Progress of Phosphodiesterase Inhibitors in Inflammatory Bowel Disease Treatment.

Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease

Discovery of Novel Imidazo[4,5- c ]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson’s Disease through a Computational Approach

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Discovery and Optimization of Dihydroquinolin-2(1 H )-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As Potential PDE4 Inhibitors.

Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[ d ]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD)

Novel naphthyridones targeting Pannexin 1 for colitis management

Identification of Novel Piperazinylquinoxaline Derivatives As Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis

Quinoline-4-methyl esters as human nonpancreatic secretory phospholipase A₂ inhibitors.

Exploration and Biological Evaluation of 1,3-Diamino-7h-pyrrol[3,2-f]quinazoline Derivatives As Dihydrofolate Reductase Inhibitors.

Discovery and Optimization of Novel h DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease

Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors